TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

OPANA ER

OXYMORPHONE HYDROCHLORIDE
Approved 2006-06-22
2
Indications
--
Phase 3 Trials
1
Priority Reviews
19
Years on Market

Details

Status
Discontinued
First Approved
2006-06-22
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

OPANA ER Approval History

Loading approval history...

What OPANA ER Treats

2 FDA approvals

Originally approved for its first indication in 2006 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OPANA ER FDA Label Details

Pro

OPANA ER Patents & Exclusivity

Latest Patent: Nov 2029

Patents (245 active)

US8871779 Expires Nov 22, 2029
US7851482 Expires Jul 10, 2029
US8808737 Expires Jun 21, 2027
+ 235 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.